First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma

R.D. Kim; D. Sarker; T. Meyer; T. Yau; T. Macarulla; J.-W. Park; S.P. Choo; A. Hollebecque; M.W. Sung; H.-Y. Lim; V. Mazzaferro; J. Trojan; A.X. Zhu; J.-H. Yoon; S. Sharma; Z.-Z. Lin; S.L. Chan; S. Faivre; L.G. Feun; C.-J. Yen; J.-F. Dufour; D.H. Palmer; J.M. Llovet; M. Manoogian; M. Tugnait; N. Stransky; M. Hagel; N.E. Kohl; C. Lengauer; C.A. Sherwin; O. Schmidt-Kittler; K.P. Hoeflich; H. Shi; B.B. Wolf; Y.-K. Kang

doi:10.1158/2159-8290.CD-19-0555

First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma

R.D. Kim, D. Sarker, T. Meyer, T. Yau, T. Macarulla, J.-W. Park, S.P. Choo, A. Hollebecque, M.W. Sung, H.-Y. Lim, V. Mazzaferro, J. Trojan, A.X. Zhu, J.-H. Yoon, S. Sharma, Z.-Z. Lin, S.L. Chan, S. Faivre, L.G. Feun, C.-J. YenJ.-F. Dufour, D.H. Palmer, J.M. Llovet, M. Manoogian, M. Tugnait, N. Stransky, M. Hagel, N.E. Kohl, C. Lengauer, C.A. Sherwin, O. Schmidt-Kittler, K.P. Hoeflich, H. Shi, B.B. Wolf, Y.-K. Kang

Fondazione IRCCS Istituto Nazionale dei Tumori

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	1696-1707
Number of pages	12
Journal	Cancer Discovery
Volume	9
Issue number	12
DOIs	https://doi.org/10.1158/2159-8290.CD-19-0555
Publication status	Published - 2019

Access to Document

10.1158/2159-8290.CD-19-0555

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85075943998&doi=10.1158%2f2159-8290.CD-19-0555&partnerID=40&md5=6ae9258a7fde1efd3ed825e0be1be41d

Cite this

Kim, R. D., Sarker, D., Meyer, T., Yau, T., Macarulla, T., Park, J-W., Choo, S. P., Hollebecque, A., Sung, M. W., Lim, H-Y., Mazzaferro, V., Trojan, J., Zhu, A. X., Yoon, J-H., Sharma, S., Lin, Z-Z., Chan, S. L., Faivre, S., Feun, L. G., ... Kang, Y-K. (2019). First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma. Cancer Discovery, 9(12), 1696-1707. https://doi.org/10.1158/2159-8290.CD-19-0555

First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma. / Kim, R.D.; Sarker, D.; Meyer, T.; Yau, T.; Macarulla, T.; Park, J.-W.; Choo, S.P.; Hollebecque, A.; Sung, M.W.; Lim, H.-Y.; Mazzaferro, V.; Trojan, J.; Zhu, A.X.; Yoon, J.-H.; Sharma, S.; Lin, Z.-Z.; Chan, S.L.; Faivre, S.; Feun, L.G.; Yen, C.-J.; Dufour, J.-F.; Palmer, D.H.; Llovet, J.M.; Manoogian, M.; Tugnait, M.; Stransky, N.; Hagel, M.; Kohl, N.E.; Lengauer, C.; Sherwin, C.A.; Schmidt-Kittler, O.; Hoeflich, K.P.; Shi, H.; Wolf, B.B.; Kang, Y.-K.

In: Cancer Discovery, Vol. 9, No. 12, 2019, p. 1696-1707.

Research output: Contribution to journal › Article › peer-review

Kim, RD, Sarker, D, Meyer, T, Yau, T, Macarulla, T, Park, J-W, Choo, SP, Hollebecque, A, Sung, MW, Lim, H-Y, Mazzaferro, V, Trojan, J, Zhu, AX, Yoon, J-H, Sharma, S, Lin, Z-Z, Chan, SL, Faivre, S, Feun, LG, Yen, C-J, Dufour, J-F, Palmer, DH, Llovet, JM, Manoogian, M, Tugnait, M, Stransky, N, Hagel, M, Kohl, NE, Lengauer, C, Sherwin, CA, Schmidt-Kittler, O, Hoeflich, KP, Shi, H, Wolf, BB & Kang, Y-K 2019, 'First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma', Cancer Discovery, vol. 9, no. 12, pp. 1696-1707. https://doi.org/10.1158/2159-8290.CD-19-0555

Kim, R.D. ; Sarker, D. ; Meyer, T. ; Yau, T. ; Macarulla, T. ; Park, J.-W. ; Choo, S.P. ; Hollebecque, A. ; Sung, M.W. ; Lim, H.-Y. ; Mazzaferro, V. ; Trojan, J. ; Zhu, A.X. ; Yoon, J.-H. ; Sharma, S. ; Lin, Z.-Z. ; Chan, S.L. ; Faivre, S. ; Feun, L.G. ; Yen, C.-J. ; Dufour, J.-F. ; Palmer, D.H. ; Llovet, J.M. ; Manoogian, M. ; Tugnait, M. ; Stransky, N. ; Hagel, M. ; Kohl, N.E. ; Lengauer, C. ; Sherwin, C.A. ; Schmidt-Kittler, O. ; Hoeflich, K.P. ; Shi, H. ; Wolf, B.B. ; Kang, Y.-K. / First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma. In: Cancer Discovery. 2019 ; Vol. 9, No. 12. pp. 1696-1707.

@article{2e429ff4c8534594876db4463dffddb2,

title = "First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma",

author = "R.D. Kim and D. Sarker and T. Meyer and T. Yau and T. Macarulla and J.-W. Park and S.P. Choo and A. Hollebecque and M.W. Sung and H.-Y. Lim and V. Mazzaferro and J. Trojan and A.X. Zhu and J.-H. Yoon and S. Sharma and Z.-Z. Lin and S.L. Chan and S. Faivre and L.G. Feun and C.-J. Yen and J.-F. Dufour and D.H. Palmer and J.M. Llovet and M. Manoogian and M. Tugnait and N. Stransky and M. Hagel and N.E. Kohl and C. Lengauer and C.A. Sherwin and O. Schmidt-Kittler and K.P. Hoeflich and H. Shi and B.B. Wolf and Y.-K. Kang",

note = "Cited By :5 Export Date: 24 February 2020",

year = "2019",

doi = "10.1158/2159-8290.CD-19-0555",

language = "English",

volume = "9",

pages = "1696--1707",

journal = "Cancer Discovery",

issn = "2159-8274",

publisher = "American Association for Cancer Research Inc.",

number = "12",

}

TY - JOUR

T1 - First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma

AU - Kim, R.D.

AU - Sarker, D.

AU - Meyer, T.

AU - Yau, T.

AU - Macarulla, T.

AU - Park, J.-W.

AU - Choo, S.P.

AU - Hollebecque, A.

AU - Sung, M.W.

AU - Lim, H.-Y.

AU - Mazzaferro, V.

AU - Trojan, J.

AU - Zhu, A.X.

AU - Yoon, J.-H.

AU - Sharma, S.

AU - Lin, Z.-Z.

AU - Chan, S.L.

AU - Faivre, S.

AU - Feun, L.G.

AU - Yen, C.-J.

AU - Dufour, J.-F.

AU - Palmer, D.H.

AU - Llovet, J.M.

AU - Manoogian, M.

AU - Tugnait, M.

AU - Stransky, N.

AU - Hagel, M.

AU - Kohl, N.E.

AU - Lengauer, C.

AU - Sherwin, C.A.

AU - Schmidt-Kittler, O.

AU - Hoeflich, K.P.

AU - Shi, H.

AU - Wolf, B.B.

AU - Kang, Y.-K.

N1 - Cited By :5 Export Date: 24 February 2020

PY - 2019

Y1 - 2019

U2 - 10.1158/2159-8290.CD-19-0555

DO - 10.1158/2159-8290.CD-19-0555

M3 - Article

VL - 9

SP - 1696

EP - 1707

JO - Cancer Discovery

JF - Cancer Discovery

SN - 2159-8274

IS - 12

ER -